155 related articles for article (PubMed ID: 18690952)
1. The risks and benefits of therapy with aldosterone receptor antagonist therapy.
Sica DA
Curr Drug Saf; 2007 Jan; 2(1):71-7. PubMed ID: 18690952
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
Sica DA
Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
[TBL] [Abstract][Full Text] [Related]
3. What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
Sica DA
Curr Cardiol Rep; 2011 Dec; 13(6):520-6. PubMed ID: 21993610
[TBL] [Abstract][Full Text] [Related]
4. The risks and benefits of aldosterone antagonists.
Sica DA
Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
Sica DA
Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
9. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
10. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
11. Comparison of agents that affect aldosterone action.
Tamargo J; Solini A; Ruilope LM
Semin Nephrol; 2014 May; 34(3):285-306. PubMed ID: 25016400
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone antagonists in the treatment of heart failure.
Marcy TR; Ripley TL
Am J Health Syst Pharm; 2006 Jan; 63(1):49-58. PubMed ID: 16373465
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone and volume management in hypertensive heart disease.
Sica DA
Semin Nephrol; 2014 May; 34(3):323-32. PubMed ID: 25016402
[TBL] [Abstract][Full Text] [Related]
15. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
16. Adverse Effects of Mineralocorticoid Receptor Antagonist Administration.
Kallistratos MS; Pittaras A; Theodoulidis I; Grassos C; Poulimenos LE; Manolis AJ
Curr Pharm Des; 2018; 24(46):5537-5541. PubMed ID: 30799782
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone: a selective aldosterone receptor antagonist (SARA).
Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
Sato A
Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
[TBL] [Abstract][Full Text] [Related]
19. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
Davis KL; Nappi JM
Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
